Back to CITADEL ADVISORS LLC CITADEL ADVISORS LLC

ATHEATHE
8 quarters

Position history for CITADEL ADVISORS LLCCITADEL ADVISORS LLC's holdings in Alterity Therapeutics Ltd

Yes. Citadel Advisors holds 37,597 shares of ATHE (Alterity Therapeutics), worth $201,896, as of its Q2 2026 13F filing. It increased the position by 17,520 shares (+87.3%) from Q1 2026. Citadel Advisors has held ATHE since Q3 2025, across 4 quarterly 13F filings.

Current Value

$201,896

Current Shares

37,597

Total Value Change

+$164,424

Total Shares Change

+19,318

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2026-Q2
Latest
Increased
37,597
+87.3%
$201,8960.0%$5.37
24
2026-Q1
Increased
20,077
+19.4%
$71,4740.0%$3.48
17
2025-Q4
Decreased
16,811
-24.1%
$51,7780.0%$3.08
0
2025-Q3
New
22,144
-
$83,4830.0%$3.76
33
2024-Q4
Exited
0
-100.0%
$00.0%$3.31
0
2024-Q3
New
11,488
-
$15,3940.0%$1.31
28
2024-Q2
Exited
0
-100.0%
$00.0%$1.81
0
2024-Q1
New
18,279
-
$37,4720.0%$2.07
31

Other major holders of ATHE: Point72 Asset Management, L.P., MORGAN STANLEY, GREENLEAF TRUST, HB Wealth Management, LLC

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used